INOTEK PHARMACEUTICALS CORP's ticker is ITEK and the CUSIP is 45780V102. A total of 66 filers reported holding INOTEK PHARMACEUTICALS CORP in Q2 2016. The put-call ratio across all filers is - and the average weighting 1.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $190,000 | +603.7% | 72,978 | +371.5% | 0.01% | +700.0% |
Q3 2017 | $27,000 | -87.4% | 15,478 | -86.3% | 0.00% | -90.9% |
Q2 2017 | $214,000 | -36.9% | 112,845 | -33.4% | 0.01% | -31.2% |
Q1 2017 | $339,000 | +229.1% | 169,545 | +1110.9% | 0.02% | +220.0% |
Q1 2016 | $103,000 | – | 14,001 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Devon Park Associates, LLC | 3,243,709 | $36,751,000 | 100.00% |
RHO CAPITAL PARTNERS INC | 2,627,790 | $29,773,000 | 10.24% |
Private Capital Advisors, Inc. | 341,000 | $3,864,000 | 1.67% |
NEXTHERA CAPITAL LP | 42,000 | $476,000 | 0.68% |
SPHERA FUNDS MANAGEMENT LTD. | 360,000 | $4,079,000 | 0.60% |
SENZAR ASSET MANAGEMENT, LLC | 309,600 | $3,507,768,000 | 0.39% |
Graticule Asia Macro Advisors LLC | 148,000 | $1,676,000 | 0.27% |
FT Options LLC | 26,421 | $299,000 | 0.22% |
EAM Investors, LLC | 128,911 | $1,461,000 | 0.19% |
Tekla Capital Management LLC | 425,000 | $4,815,000 | 0.18% |